Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2009, Article ID 369129, 7 pages
http://dx.doi.org/10.1155/2009/369129
Research Article

Clinical Significance of Epigenetic Inactivation of hMLH1 and BRCA1 in Tunisian Patients with Invasive Breast Carcinoma

1Unitéde Génétique du cancer et Production de protéines thérapeutiques, Centre de Biotechnologie de Sfax, route Sidi Mansour, BP “1177”, 3018 Sfax, Tunisia
2Centre Hospitalo, Universitaire Habib Bourguiba, 3000 Sfax, Tunisia

Received 14 February 2009; Accepted 19 May 2009

Academic Editor: Xin-yuan Guan

Copyright © 2009 Sondes Karray-Chouayekh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. J. Feuer, L.-M. Wun, C. C. Boring, W. D. Flanders, M. J. Timmel, and T. Tong, “The lifetime risk of developing breast cancer,” Journal of the National Cancer Institute, vol. 85, no. 11, pp. 892–897, 1993. View at Google Scholar
  2. N. Mourali, L. R. Muenz, F. Tabbane, S. Belhassen, J. Bahi, and P. H. Levine, “Epidemiologic features of rapidly progressing breast cancer in Tunisia,” Cancer, vol. 46, no. 12, pp. 2741–2746, 1980. View at Google Scholar
  3. D. M. Parkin, J. Ferlay, M. Hamdi-Cherif et al., “Breast Cancer,” in Cancer in Africa: Epidemiology and Prevention, vol. 153, pp. 262–267, IARC Scientific, Lyon, France, 2003. View at Google Scholar
  4. J. Russo, X. Yang, Y. F. Hu et al., “Biological and molecular basis of human breast cancer,” Frontiers in Bioscience, vol. 3, pp. D944–D960, 1998. View at Google Scholar
  5. P. A. Jones and S. B. Baylin, “The fundamental role of epigenetic events in cancer,” Nature Reviews Genetics, vol. 3, no. 6, pp. 415–428, 2002. View at Google Scholar
  6. M. Esteller, “CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future,” Oncogene, vol. 21, no. 35, pp. 5427–5440, 2002. View at Publisher · View at Google Scholar
  7. M. Esteller, P. G. Corn, S. B. Baylin, and J. G. Herman, “A gene hypermethylation profile of human cancer,” Cancer Research, vol. 61, no. 8, pp. 3225–3229, 2001. View at Google Scholar
  8. S. B. Baylin and J. E. Ohm, “Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction?” Nature Reviews Cancer, vol. 6, no. 2, pp. 107–116, 2006. View at Publisher · View at Google Scholar
  9. B. B. Asch and M. H. Barcellos-Hoff, “Epigenetics and breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 6, no. 2, pp. 151–152, 2001. View at Publisher · View at Google Scholar
  10. U. Lehmann, F. Langer, H. Feist, S. Glockner, B. Hasemeier, and H. Kreipe, “Quantitative assessment of promoter hypermethylation during breast cancer development,” American Journal of Pathology, vol. 160, no. 2, pp. 605–612, 2002. View at Google Scholar
  11. M. Widschwendter and P. A. Jones, “DNA methylation and breast carcinogenesis,” Oncogene, vol. 21, no. 35, pp. 5462–5482, 2002. View at Publisher · View at Google Scholar
  12. M. Szyf, P. Pakneshan, and S. A. Rabbani, “DNA methylation and breast cancer,” Biochemical Pharmacology, vol. 68, no. 6, pp. 1187–1197, 2004. View at Publisher · View at Google Scholar
  13. Y. K. Bae, A. Brown, E. Garrett et al., “Hypermethylation in histologically distinct classes of breast cancer,” Clinical Cancer Research, vol. 10, no. 18, part 1, pp. 5998–6005, 2004. View at Publisher · View at Google Scholar
  14. J. S. Lee, P.-K. Lo, M. J. Fackler et al., “A comparative study of Korean with Caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in Korean women,” Cancer Biology and Therapy, vol. 6, no. 7, pp. 1114–1120, 2007. View at Google Scholar
  15. M. Hachana, M. Trimeche, S. Ziadi, K. Amara, and S. Korbi, “Evidence for a role of the Simian Virus 40 in human breast carcinomas,” Breast Cancer Research and Treatment, vol. 113, no. 1, pp. 43–58, 2009. View at Publisher · View at Google Scholar
  16. A. Catteau, W. H. Harris, C.-F. Xu, and E. Solomon, “Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics,” Oncogene, vol. 18, no. 11, pp. 1957–1965, 1999. View at Google Scholar
  17. T. Bianco, C. T. Georgia, C. A. W. David, E. C. John, and D. Alexander, “Tumor specific distribution of BRCA1 promoter region methylation supports a pathogenic role in breast and ovarian cancer,” Carcinogenesis, vol. 21, no. 2, pp. 147–151, 2000. View at Google Scholar
  18. D. T. Butcher and D. I. Rodenhiser, “Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours,” European Journal of Cancer, vol. 43, no. 1, pp. 210–219, 2007. View at Publisher · View at Google Scholar
  19. H. Murata, N. H. Khattar, Y. Kang, L. Gu, and G.-M. Li, “Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability,” Oncogene, vol. 21, no. 37, pp. 5696–5703, 2002. View at Publisher · View at Google Scholar
  20. H. Murata, N. H. Khattar, L. Gu, and G.-M. Li, “Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer,” Cancer Letters, vol. 223, no. 1, pp. 143–150, 2005. View at Publisher · View at Google Scholar
  21. T. Jascur and C. R. Boland, “Structure and function of the components of the human DNA mismatch repair system,” International Journal of Cancer, vol. 119, no. 9, pp. 2030–2035, 2006. View at Publisher · View at Google Scholar
  22. D. C. Thomas, A. Umar, and T. A. Kunkel, “Microsatellite instability and mismatch repair defects in cancer,” Mutation Research, vol. 350, no. 1, pp. 201–205, 1996. View at Google Scholar
  23. J. Jiricny, “The multifaceted mismatch-repair system,” Nature Reviews Molecular Cell Biology, vol. 7, no. 5, pp. 335–346, 2006. View at Publisher · View at Google Scholar
  24. A. Catteau and J. R. Morris, “BRCA1 methylation: a significant role in tumour development?” Seminars in Cancer Biology, vol. 12, no. 5, pp. 359–371, 2002. View at Publisher · View at Google Scholar
  25. C. W. Elston, I. O. Ellis, H. Goulging, and S. E. Pindre, “Role of pathology in the prognosis and management of breast cancer,” in Systemic Pathology, C. W. Elston and I. O. Ellis, Eds., vol. 13, pp. 385–433, 3rd edition, 1998. View at Google Scholar
  26. L. H. Sobin and Ch. Wittekind, Eds., International Union Against Cancer, TNM Classification of Malignant Tumours, Wiley-Liss, New York, NY, USA, 5th edition, 1997.
  27. J. Sambrook and D. W. Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2001.
  28. J. G. Herman, J. R. Graff, S. Myohanen, B. D. Nelkin, and S. B. Baylin, “Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9821–9826, 1996. View at Publisher · View at Google Scholar
  29. R. A. Naqvi, A. Hussain, S. S. V. Deo et al., “Hypermethylation analysis of mismatch repair genes (hmlh1 and hmsh2) in locally advanced breast cancers in Indian women,” Human Pathology, vol. 39, no. 5, pp. 672–680, 2008. View at Publisher · View at Google Scholar
  30. V. Birgisdottir, O. A. Stefansson, S. K. Bodvarsdottir, H. Hilmarsdottir, J. G. Jonasson, and J. E. Eyfjord, “Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer,” Breast Cancer Research, vol. 8, no. 4, pp. 1–10, 2006. View at Publisher · View at Google Scholar
  31. M. Wei, T. A. Grushko, J. Dignam et al., “BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy,” Cancer Research, vol. 65, no. 23, pp. 10692–10699, 2005. View at Publisher · View at Google Scholar
  32. S. Li, M. Rong, and B. Iacopetta, “DNA hypermethylation in breast cancer and its association with clinicopathological features,” Cancer Letters, vol. 237, no. 2, pp. 272–280, 2006. View at Publisher · View at Google Scholar
  33. M. J. Duffy, “Estrogen receptors: role in breast cancer,” Critical Reviews in Clinical Laboratory Sciences, vol. 43, no. 4, pp. 325–347, 2006. View at Google Scholar
  34. J. A. Rusiecki, T. R. Holford, S. H. Zahm, and T. Zheng, “Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status,” Cancer Detection and Prevention, vol. 29, no. 5, pp. 419–426, 2005. View at Publisher · View at Google Scholar
  35. M. Campan, D. J. Weisenberger, and P. W. Laird, “DNA methylation profiles of female steroid hormone-driven human malignancies,” Current Topics in Microbiology and Immunology, vol. 310, pp. 141–178, 2006. View at Google Scholar
  36. M. Widschwendter, K. D. Siegmund, H. M. Müller et al., “Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen,” Cancer Research, vol. 64, no. 11, pp. 3807–3813, 2004. View at Publisher · View at Google Scholar
  37. J. Rhee, S.-W. Han, D.-Y. Oh et al., “The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer,” BMC Cancer, vol. 8, no. 308, pp. 1–8, 2008. View at Publisher · View at Google Scholar
  38. W. J. Irvin Jr. and L. A. Carey, “What is triple-negative breast cancer?” European Journal of Cancer, vol. 44, no. 18, pp. 2799–2805, 2008. View at Publisher · View at Google Scholar
  39. X. Xu, M. D. Gammon, Y. Zhang et al., “BRCA1 promoter methylation is associated with increased mortality among women with breast cancer,” Breast Cancer Research and Treatment, vol. 115, no. 2, pp. 397–404, 2009. View at Publisher · View at Google Scholar